Hahnemann Pure Drugcompany Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.91 M
as on 16-11-2024
- Company Age 27 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 0.29%
(FY 2023)
- Profit 1.73%
(FY 2023)
- Ebitda 7.62%
(FY 2023)
- Net Worth 16.09%
(FY 2023)
- Total Assets 12.10%
(FY 2023)
About Hahnemann Pure Drugcompany
The Corporate was formerly known as Hahneman Pure Drug Company Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.91 M, as per Ministry of Corporate Affairs (MCA) records.
Nadim Rahman and Iram Shakeel serve as directors at the Company.
- CIN/LLPIN
U24231UP1997PTC022630
- Company No.
022630
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Sep 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- LocationUttar Pradesh, Uttar Pradesh
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Hahnemann Pure Drugcompany Private Limited offer?
Hahnemann Pure Drugcompany Private Limited offers a wide range of products and services, including Homeopathic Medicines & Remedies, Homeopathic Drugs, Digestive System Drugs & Medicines, Digestive Drugs, Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Biometrics & Access Control Devices, Biometric Access Control System, Child and Baby Care Products, Baby Care Products.
Who are the key members and board of directors at Hahnemann Pure Drugcompany?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nadim Rahman  | Director | 18-Sep-1997 | Current |
| Iram Shakeel | Director | 15-Oct-2021 | Current |
Financial Performance of Hahnemann Pure Drugcompany.
Hahnemann Pure Drugcompany Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.29% increase. The company also saw a slight improvement in profitability, with a 1.73% increase in profit. The company's net worth Soared by an impressive increase of 16.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hahnemann Pure Drugcompany?
In 2023, Hahnemann Pure Drugcompany had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hahnemann Pure Drugcompany?
Hahnemann Pure Drugcompany has a workforce of 33 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hahnemann Pure Drugcompany, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hahnemann Pure Drugcompany's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
